Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

Erhan Ararat

Concepts (111)

Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Breast Neoplasms
11
2015
1189
1.090
Why?
Organoids
2
2022
36
0.970
Why?
Anti-Asthmatic Agents
1
2023
29
0.860
Why?
Asthma
2
2024
282
0.850
Why?
Metformin
1
2023
65
0.820
Why?
Lung
3
2022
512
0.720
Why?
Aspirin
2
2011
111
0.660
Why?
Cystic Fibrosis
1
2021
151
0.630
Why?
Diabetes Mellitus
1
2021
284
0.580
Why?
Neoadjuvant Therapy
3
2013
119
0.450
Why?
Antineoplastic Combined Chemotherapy Protocols
3
2011
1003
0.360
Why?
Diphosphonates
1
2010
90
0.330
Why?
Imidazoles
1
2010
128
0.330
Why?
Neoplasm Metastasis
1
2010
235
0.330
Why?
Protein Phosphatase 1
1
2009
7
0.330
Why?
Adolescent
5
2024
6475
0.320
Why?
Losartan
1
2009
27
0.320
Why?
Mitogen-Activated Protein Kinase 3
1
2009
48
0.320
Why?
Mitogen-Activated Protein Kinase 1
1
2009
49
0.320
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2010
122
0.320
Why?
Angiotensin II Type 1 Receptor Blockers
1
2009
43
0.320
Why?
Isoenzymes
1
2009
168
0.310
Why?
MAP Kinase Signaling System
1
2009
118
0.310
Why?
Genetic Predisposition to Disease
1
2011
509
0.300
Why?
Child
4
2024
6877
0.290
Why?
Humans
20
2024
50389
0.250
Why?
Antineoplastic Agents
2
2011
1178
0.250
Why?
Allergy and Immunology
1
2024
19
0.230
Why?
Female
15
2024
26981
0.210
Why?
Adrenal Cortex Hormones
1
2023
100
0.210
Why?
Preoperative Care
1
2024
170
0.210
Why?
Home Care Services
1
2023
72
0.200
Why?
Spinocerebellar Ataxias
1
2022
4
0.200
Why?
Medicaid
1
2024
258
0.200
Why?
Young Adult
4
2023
4064
0.190
Why?
Body Height
1
2021
65
0.180
Why?
Mass Screening
1
2024
348
0.180
Why?
Respiration, Artificial
1
2023
292
0.180
Why?
Anthracyclines
2
2011
29
0.180
Why?
Disease Progression
1
2023
823
0.180
Why?
Nutritional Status
1
2021
136
0.180
Why?
Incidence
2
2011
1017
0.150
Why?
Child, Preschool
2
2024
3908
0.140
Why?
Retrospective Studies
4
2024
6223
0.130
Why?
Adult
5
2023
13568
0.130
Why?
Multiple Myeloma
1
2010
2949
0.130
Why?
Muscular Dystrophy, Duchenne
1
2015
24
0.120
Why?
Receptors, Progesterone
2
2013
63
0.110
Why?
Receptor, erbB-2
2
2013
75
0.110
Why?
Cardiomyopathies
1
2015
119
0.110
Why?
Receptors, Estrogen
2
2013
130
0.110
Why?
Axilla
1
2013
91
0.110
Why?
Male
5
2024
25718
0.100
Why?
Prognosis
3
2015
1979
0.100
Why?
Heart
1
2015
336
0.100
Why?
Phenotype
1
2015
736
0.100
Why?
Lymphatic Metastasis
1
2013
227
0.100
Why?
Survival Rate
2
2013
915
0.100
Why?
Dacarbazine
1
2011
8
0.100
Why?
Opportunistic Infections
1
2011
59
0.090
Why?
Lymph Nodes
1
2013
258
0.090
Why?
Deoxycytidine
1
2011
28
0.090
Why?
Antineoplastic Agents, Alkylating
1
2011
74
0.090
Why?
Fluorouracil
1
2011
56
0.090
Why?
Genes, BRCA1
1
2011
19
0.090
Why?
Phthalazines
1
2011
20
0.090
Why?
Drugs, Generic
1
2010
6
0.090
Why?
Neoplasm Recurrence, Local
2
2013
634
0.090
Why?
Taxoids
1
2010
37
0.090
Why?
Tamoxifen
1
2010
59
0.090
Why?
Antineoplastic Agents, Hormonal
1
2010
49
0.090
Why?
Piperazines
1
2011
118
0.080
Why?
Captopril
1
2009
13
0.080
Why?
Angiotensin-Converting Enzyme Inhibitors
1
2009
74
0.080
Why?
p38 Mitogen-Activated Protein Kinases
1
2009
96
0.080
Why?
Chemotherapy, Adjuvant
3
2015
121
0.080
Why?
Enzyme Activation
1
2009
272
0.080
Why?
Muscle, Smooth, Vascular
1
2009
131
0.080
Why?
Aorta
1
2009
163
0.070
Why?
Ventricular Function, Left
1
2009
167
0.070
Why?
Age Factors
1
2011
1104
0.070
Why?
Follow-Up Studies
1
2011
2219
0.060
Why?
Rats, Sprague-Dawley
1
2009
1582
0.060
Why?
Myocardial Infarction
1
2009
398
0.060
Why?
Apoptosis
1
2010
1094
0.060
Why?
Mutation
1
2011
1292
0.060
Why?
Treatment Outcome
2
2013
5230
0.060
Why?
Respiration
1
2023
100
0.050
Why?
Heart Failure
1
2009
526
0.050
Why?
Tracheostomy
1
2023
71
0.050
Why?
Rats
1
2009
3287
0.050
Why?
Animals
2
2022
13173
0.050
Why?
Stem Cells
1
2022
171
0.050
Why?
Emergency Service, Hospital
1
2024
482
0.040
Why?
Epithelial Cells
1
2022
210
0.040
Why?
Hospitalization
1
2024
668
0.040
Why?
Cell Differentiation
1
2022
651
0.040
Why?
Arkansas
1
2024
1991
0.040
Why?
Infant
1
2024
3601
0.030
Why?
Respiratory Function Tests
1
2015
88
0.030
Why?
Aged
3
2013
9590
0.030
Why?
United States
1
2024
4913
0.030
Why?
Neoplasm Invasiveness
1
2013
269
0.030
Why?
Disease-Free Survival
1
2013
450
0.020
Why?
Mice
1
2022
5688
0.020
Why?
Chemistry, Pharmaceutical
1
2010
33
0.020
Why?
Arthralgia
1
2010
43
0.020
Why?
Drug Administration Schedule
1
2010
369
0.020
Why?
Middle Aged
2
2013
12460
0.020
Why?
Risk Factors
1
2015
3692
0.020
Why?
Aged, 80 and over
1
2013
3180
0.020
Why?
Ararat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description